Health Care • Biotechnology: Pharmaceutical Preparations
$143.85 ▲ +0.02
(+0.01%)
MKT CAP: $6.01B • VOL: 513.7K
52W L $32 52W H $147
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$121
MEDIAN
$161
MEAN
$164
HIGH
$196
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE MANE TAPE
MANE // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $174.06 | $165.43 | 2025-02-14 | $130.90 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $181.25 | $169.74 | 2025-02-06 | $135.22 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $163.99 | $158.24 | 2025-01-29 | $138.10 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $146.73 | — | 2025-01-17 | $140.97 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $126.59 | $136.66 | 2025-01-09 | $128.03 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $171.18 | $149.60 | 2024-12-18 | $125.15 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $139.53 | $145.29 | 2024-12-04 | $133.78 | -4.3% | 48% | C |